Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Efficacy of Converting From Intravenous or Subcutaneous rHuEPO to Intravenous Darbepoetin Alfa (Aranesp®) in Subjects With Chronic Kidney Disease Receiving Haemodialysis

NCT00116701 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00116701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00116701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Efficacy of Converting From Intravenous or Subcutaneous rHuEPO to Intravenous Darbepoetin Alfa (Aranesp®) in Subjects With Chronic Kidney Disease Receiving Haemodialysis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2005
Completion date
Not reported
Enrollment
200
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

kidney disease